Engraftment of human blood malignancies to the turkey embryo: A robust new in vivo model

Igor Grinberg; Arbel Reis; Avivit Ohana; Moran Taizi; Michal Cipok; Sigal Tavor; Deborah Rund; Varda R. Deutsch; Ronald S. Goldstein

doi:10.1016/j.leukres.2009.02.009

Engraftment of human blood malignancies to the turkey embryo: A robust new in vivo model

Igor Grinberg, Arbel Reis, Avivit Ohana, Moran Taizi, Michal Cipok, Sigal Tavor, Deborah Rund, Varda R. Deutsch, Ronald S. Goldstein

The Mina and Everard Goodman Faculty of Life Sciences

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Xenografting of human blood malignancies to immunodeficient SCID mice is a powerful research tool. We evaluate here whether the immunodeficient turkey embryo can also serve as a xenograft host for human blood malignancies. Human leukemia, lymphoma and myeloma lines engrafted robustly into medullary and extramedullary tissues of turkey embryos as detected by PCR, FACS and histology in 8-10 days. Four of eleven patient AML samples also engrafted the bone marrow. Grafts of two lines responded to chemotherapy with doxorubicin. The turkey embryo therefore has the potential to be a complementary xenograft model for the study of human blood malignancies.

Original language	English
Pages (from-to)	1417-1426
Number of pages	10
Journal	Leukemia Research
Volume	33
Issue number	10
DOIs	https://doi.org/10.1016/j.leukres.2009.02.009
State	Published - Oct 2009

Bibliographical note

Funding Information:
Thanks to Tsvee Lapidot for providing the G2 cells, to Ada Refaeli for providing the HL-60 line and Galit Granot for the HBL-2 cells. Thanks to Chaya Morgenstern, Dr. Sigi Kay and Shoshana Baron for excellent technical and administrative assistance. Undergraduate interns Alexandra Polsky and Karen Levi provided invaluable assistance. This research was supported by grants by the Horowitz Foundation for Applied Biomedical Research to R.S.G. and the Israel Ministry of Health (Weinkselbaum family medical research fund), the Israel Cancer Association through a donation from Don and Donna Sherman and Caesaria Edmond Benjamin de Rothchild Foundation (V.R.D.). None of the granting agencies participated in any aspect of the study.

Keywords

Chemotherapy testing
Chick embryo
Xenografts

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2009.02.009

Cite this

@article{c36ece93102d4b7f88cb6b6bec2cf32c,

title = "Engraftment of human blood malignancies to the turkey embryo: A robust new in vivo model",

abstract = "Xenografting of human blood malignancies to immunodeficient SCID mice is a powerful research tool. We evaluate here whether the immunodeficient turkey embryo can also serve as a xenograft host for human blood malignancies. Human leukemia, lymphoma and myeloma lines engrafted robustly into medullary and extramedullary tissues of turkey embryos as detected by PCR, FACS and histology in 8-10 days. Four of eleven patient AML samples also engrafted the bone marrow. Grafts of two lines responded to chemotherapy with doxorubicin. The turkey embryo therefore has the potential to be a complementary xenograft model for the study of human blood malignancies.",

keywords = "Chemotherapy testing, Chick embryo, Xenografts",

author = "Igor Grinberg and Arbel Reis and Avivit Ohana and Moran Taizi and Michal Cipok and Sigal Tavor and Deborah Rund and Deutsch, {Varda R.} and Goldstein, {Ronald S.}",

note = "Funding Information: Thanks to Tsvee Lapidot for providing the G2 cells, to Ada Refaeli for providing the HL-60 line and Galit Granot for the HBL-2 cells. Thanks to Chaya Morgenstern, Dr. Sigi Kay and Shoshana Baron for excellent technical and administrative assistance. Undergraduate interns Alexandra Polsky and Karen Levi provided invaluable assistance. This research was supported by grants by the Horowitz Foundation for Applied Biomedical Research to R.S.G. and the Israel Ministry of Health (Weinkselbaum family medical research fund), the Israel Cancer Association through a donation from Don and Donna Sherman and Caesaria Edmond Benjamin de Rothchild Foundation (V.R.D.). None of the granting agencies participated in any aspect of the study. ",

year = "2009",

month = oct,

doi = "10.1016/j.leukres.2009.02.009",

language = "אנגלית",

volume = "33",

pages = "1417--1426",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "10",

}

TY - JOUR

T1 - Engraftment of human blood malignancies to the turkey embryo

T2 - A robust new in vivo model

AU - Grinberg, Igor

AU - Reis, Arbel

AU - Ohana, Avivit

AU - Taizi, Moran

AU - Cipok, Michal

AU - Tavor, Sigal

AU - Rund, Deborah

AU - Deutsch, Varda R.

AU - Goldstein, Ronald S.

N1 - Funding Information: Thanks to Tsvee Lapidot for providing the G2 cells, to Ada Refaeli for providing the HL-60 line and Galit Granot for the HBL-2 cells. Thanks to Chaya Morgenstern, Dr. Sigi Kay and Shoshana Baron for excellent technical and administrative assistance. Undergraduate interns Alexandra Polsky and Karen Levi provided invaluable assistance. This research was supported by grants by the Horowitz Foundation for Applied Biomedical Research to R.S.G. and the Israel Ministry of Health (Weinkselbaum family medical research fund), the Israel Cancer Association through a donation from Don and Donna Sherman and Caesaria Edmond Benjamin de Rothchild Foundation (V.R.D.). None of the granting agencies participated in any aspect of the study.

PY - 2009/10

Y1 - 2009/10

N2 - Xenografting of human blood malignancies to immunodeficient SCID mice is a powerful research tool. We evaluate here whether the immunodeficient turkey embryo can also serve as a xenograft host for human blood malignancies. Human leukemia, lymphoma and myeloma lines engrafted robustly into medullary and extramedullary tissues of turkey embryos as detected by PCR, FACS and histology in 8-10 days. Four of eleven patient AML samples also engrafted the bone marrow. Grafts of two lines responded to chemotherapy with doxorubicin. The turkey embryo therefore has the potential to be a complementary xenograft model for the study of human blood malignancies.

AB - Xenografting of human blood malignancies to immunodeficient SCID mice is a powerful research tool. We evaluate here whether the immunodeficient turkey embryo can also serve as a xenograft host for human blood malignancies. Human leukemia, lymphoma and myeloma lines engrafted robustly into medullary and extramedullary tissues of turkey embryos as detected by PCR, FACS and histology in 8-10 days. Four of eleven patient AML samples also engrafted the bone marrow. Grafts of two lines responded to chemotherapy with doxorubicin. The turkey embryo therefore has the potential to be a complementary xenograft model for the study of human blood malignancies.

KW - Chemotherapy testing

KW - Chick embryo

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=67649362255&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.02.009

DO - 10.1016/j.leukres.2009.02.009

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 19297019

AN - SCOPUS:67649362255

SN - 0145-2126

VL - 33

SP - 1417

EP - 1426

JO - Leukemia Research

JF - Leukemia Research

IS - 10

ER -

Engraftment of human blood malignancies to the turkey embryo: A robust new in vivo model

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this